Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated…